Indeed, EIF4A3‐silencing abrogated FGF19 signalling in liver cancer cells in terms of the phosphorylation of key FGFR4‐downstream effectors (AKT, ERK, SRC and GSK3B),24 thus suggesting a role of this splicing factor in sustaining the FGF19/FGFR4 oncogenic pathway. This evidence concerns the gene GSK3B and liver cancer.